...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Materials science & engineering >The adjuvant effect of C_(60)(OH)_(22) nanoparticles promoting both humoral and cellular immune responses to HCV recombinant proteins
【24h】

The adjuvant effect of C_(60)(OH)_(22) nanoparticles promoting both humoral and cellular immune responses to HCV recombinant proteins

机译：C_（60）（OH）_（22）纳米颗粒的佐剂促进对HCV重组蛋白的体液和细胞免疫反应

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hepatitis c virus (HCV) infection is one of major causes for chronic liver diseases worldwide and could lead to death. Development of effective HCV vaccines is a powerful auxiliary method of existing treatments. Adjuvants are necessary for modem vaccines to promote immune responses. Among the various nanomaterials that have been developed, multihydroxylated fullerene (C-60(OH)(22)) has been proved as an efficient adjuvant for human immunodeficiency virus DNA vaccine. Here, we utilized three types of HCV recombinant proteins as antigens to investigate the activity of C-60(OH)(22) as a protein vaccine adjuvant. The proteins were carried by C-60(OH)(22) in a way of surface adsorption and self-assemble encapsulation. C-60(OH)(22) at a relatively low dose was sufficient to promote both humeral and cellular immune responses to HCV protein antigens and reduce the usage of antigen. These results demonstrated the positive adjuvant properties of C-60(OH)(22) when applied to protein vaccines.
机译：丙型肝炎病毒（HCV）感染是全世界慢性肝病的主要原因之一，并可能导致死亡。开发有效的HCV疫苗是现有疗法的有力辅助手段。佐剂是现代疫苗促进免疫反应所必需的。在已开发的各种纳米材料中，多羟基富勒烯（C-60（OH）（22））已被证明是人类免疫缺陷病毒DNA疫苗的有效佐剂。在这里，我们利用三种类型的HCV重组蛋白作为抗原来研究C-60（OH）（22）作为蛋白疫苗佐剂的活性。 C-60（OH）（22）通过表面吸附和自组装封装的方式携带蛋白质。较低剂量的C-60（OH）（22）足以促进针对HCV蛋白抗原的肱骨和细胞免疫反应，并减少抗原的使用。这些结果证明了将C-60（OH）（22）应用于蛋白疫苗具有积极的佐剂特性。

著录项

  • 来源
    《Materials science & engineering》 |2019年第4期|753-759|共7页
  • 作者

    Liu Jing; Feng Xiaoyan; Chen Zhiyun; Yang Xiqin; Shen Ziyi; Guo Mengyu; Deng Fangling; Liu Ying; Zhang Heqiu; Chen Chunying;

  • 作者单位

    Northwest Univ, Coll Life Sci, Xian 710069, Peoples R China|Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China|Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, Beijing 100190, Peoples R China;

    Acad Mil Med Sci, Inst Mil Cognit & Brain Sci, Beijing 100850, Peoples R China;

    Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China|Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, Beijing 100190, Peoples R China;

    Acad Mil Med Sci, Inst Mil Cognit & Brain Sci, Beijing 100850, Peoples R China;

    Northwest Univ, Coll Life Sci, Xian 710069, Peoples R China;

    Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China|Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, Beijing 100190, Peoples R China;

    Wuhan Univ, Wuhan 430072, Hubei, Peoples R China;

    Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China|Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, Beijing 100190, Peoples R China;

    Acad Mil Med Sci, Inst Mil Cognit & Brain Sci, Beijing 100850, Peoples R China;

    Natl Ctr Nanosci & Technol, CAS Key Lab Biomed Effects Nanomat & Nanosafety, Beijing 100190, Peoples R China|Natl Ctr Nanosci & Technol, CAS Ctr Excellence Nanosci, Beijing 100190, Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    C-60(OH)(22); Nanoparticles; Immune responses; HCV recombinant proteins; Vaccine; Adjuvant;

    机译：C-60（OH）（22）;纳米颗粒;免疫应答;HCV重组蛋白;疫苗;佐剂;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号